← Back to Screener
Immix Biopharma, Inc. Common Stock (IMMX)
Price$7.93
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)78.66%
Price vs S&P 500 (4W)-18.66%
VGM Score71.04
Market Capitalization$564.54M
All Metrics
Book Value / Share (Quarterly)$1.59
P/TBV (Annual)7.20x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.62
Price vs S&P 500 (YTD)43.47%
EPS (TTM)$-0.91
10-Day Avg Trading Volume1.60M
EPS Excl Extra (TTM)$-0.91
EPS (Annual)$-0.89
ROI (Annual)-31.39%
Cash / Share (Quarterly)$1.71
ROA (Last FY)-28.08%
EBITD / Share (TTM)$-0.91
ROE (5Y Avg)-97.32%
Cash Flow / Share (Annual)$-0.47
P/B Ratio6.69x
P/B Ratio (Quarterly)5.72x
Net Income / Employee (Annual)$-1,401,800
Net Interest Coverage (TTM)-0.06x
ROA (TTM)-59.20%
EPS Incl Extra (Annual)$-0.89
Current Ratio (Annual)10.01x
Quick Ratio (Quarterly)8.63x
3-Month Avg Trading Volume0.94M
52-Week Price Return262.10%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.01
52-Week High$11.61
EPS Excl Extra (Annual)$-0.89
CapEx CAGR (5Y)159.54%
26-Week Price Return86.59%
Quick Ratio (Annual)9.95x
13-Week Price Return-7.14%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)8.76x
Enterprise Value$485.29M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$1.90
3-Month Return Std Dev79.49%
Net Income / Employee (TTM)$-1,665,800
ROE (Last FY)-31.39%
Net Interest Coverage (Annual)-0.05x
EPS Basic Excl Extra (Annual)$-0.89
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.91
ROI (TTM)-73.23%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.95
Price vs S&P 500 (52W)237.73%
Year-to-Date Return51.63%
5-Day Price Return-13.99%
EPS Normalized (Annual)$-0.89
ROA (5Y Avg)-77.78%
Month-to-Date Return-11.89%
Cash Flow / Share (TTM)$-0.93
EBITD / Share (Annual)$-0.90
ROI (5Y Avg)-97.24%
EPS Basic Excl Extra (TTM)$-0.91
P/TBV (Quarterly)4.79x
P/B Ratio (Annual)2.94x
Book Value / Share (Annual)$1.77
Price vs S&P 500 (13W)-15.40%
Beta0.13x
Revenue / Share (TTM)$0.00
ROE (TTM)-73.23%
52-Week Low$1.94
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.18est. -0.21
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.14
4.13
4.10
4.10
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
IMMXImmix Biopharma, Inc. Common Stock | — | — | B | $7.93 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Immix Biopharma is a clinical-stage biopharmaceutical company developing novel cell therapies for oncology and inflammatory diseases using its proprietary TME Normalization Technology. This platform enables therapeutics to penetrate tumors and simultaneously target multiple components of the tumor microenvironment. The company's pipeline includes CAR-T candidate NXC-201 for autoimmune diseases and IMX-110 for soft tissue sarcoma.